Syngene International Limited — Updates, 29-04-2026: Press Release

Syngene's FY26 revenue grew 3% to Rs 3,739 Cr, but PAT dropped 20% to Rs 380 Cr, impacted by a biologics client and new facility costs. The Board proposed a Rs 1.25/share dividend. New MD/CEO appointed, and the company is expanding Antibody-Drug Conjugate (ADC) capabilities.